ClinicalTrials.gg
RecruitingNCT06561451Updated Feb 2, 2026

Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia

An interventional study of intracytoplasmic sperm injection and artificial oocyte activation and intracytoplasmic sperm injection in Male Infertility and Teratospermia, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Recruiting at 1 site in China. Open to participants aged 20 Years to 37 Years. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
20 Years to 37 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Infertility, Male with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Infertility, Male · China.

Started
2024
the only one that year
No phase
4 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
ShangHai Ji Ai Genetics & IVF Institute

Among the 10 studies in Infertility, Male with a site in China, this one is the only one that started in 2024, is one of 4 with no phase, and was the 9th registered.

Infertility, Male

283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.

Browse Infertility, Male studies →

Open to participants now

3 of the 10 studies in Infertility, Male with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Infertility, Male studies recruiting now, 17 (41%) set no upper age limit and 24 (59%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 20 Years to 37 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Infertility, Male with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the live birth rate between intracytoplasmic sperm injection (ICSI) and artificial oocyte activation (AOA) vs intracytoplasmic sperm injection alone in patients with teratospermia. The hypothesis is the live birth rate following ICSI and AOA is significantly higher than that by ICSI alone in patients with teratospermia. This is a randomized controlled trial. Participants will be randomly assigned into one of the two groups:

ICSI+AOA group: a single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.

ICSI alone group: a single sperm will be injected within 4 hours after the follicular aspiration.

03

Conditions studied

  • Male Infertility
  • Teratospermia

Browse trials for

04

Who can participate

Ages eligible
20 Years to 37 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of women 20-37 years at the time of ovarian stimulation for ICSI
  2. At least three matured oocytes Severe teratozoospermia: defined as abnormal sperm morphology ranging between 99-100%, including globozoospermia and tapered-head.

Exclusion criteria

Exclusion Criteria:

  1. Presence of hydrosalpinx which is not surgically treated
  2. Undergoing preimplantation genetic testing
  3. Recurrent pregnancy loss (defined as two or more previous spontaneous pregnancy losses)
  4. Known uterine abnormality (e.g., uterine congenital malformation; untreated uterine septum, adenomyosis, or submucous myoma; endometrial polyps; or intrauterine adhesions)
  5. Abnormal parental karyotyping, or Medical conditions that assisted reproductive technology or pregnancy is
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    ICSI+AOA group

    ICSI+AOA group: a single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.

    Procedure: intracytoplasmic sperm injection and artificial oocyte activation

  • Active comparator
    ICSI group

    a single sperm will be injected within 4 hours after the follicular aspiration.

    Procedure: intracytoplasmic sperm injection

Interventions

  • Procedureintracytoplasmic sperm injection and artificial oocyte activation

    A single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.

  • Procedureintracytoplasmic sperm injection

    A single sperm will be injected within 4 hours after the follicular aspiration.

06

What researchers measure

Primary outcomes

  1. Live birth

    Delivery ≥22 weeks of gestation with heartbeat and breath.

    Time frame: 1 year after embryo transfer

Secondary outcomes

  1. Fertilization rate

    Fertilized oocytes with two pronuclei per MII oocyte injected

    Time frame: 1 day after oocyte retrieval

  2. High-quality embryos on Day 3

    Seven or eight blastomeres of equal-size and \<20% fragmentation by volume

    Time frame: 3 days after oocyte retrieval

  3. hCG positivity

    Serum hCG level ≥10mIU/mL

    Time frame: 14 days after embryo transfer

  4. Number and grading of embryos/blastocysts

    Number and grading of embryos/blastocysts suitable for freezing and transfer

    Time frame: 6 days after oocyte retrieval

  5. Clinical pregnancy

    the presence of an intrauterine gestational sac on transvaginal ultrasound at 6 gestational weeks.

    Time frame: 6 weeks of gestation

  6. Ongoing pregnancy

    a viable pregnancy beyond 12 weeks of gestation

    Time frame: 12 weeks of gestation

  7. Multiple pregnancy

    presence of more than one intrauterine sac at 6 weeks of gestation

    Time frame: 6 weeks of gestation

  8. Cumulative live birth rate (within 6 months after randomization)

    Any live birth arising from embryo transfer within 6 months after randomization

    Time frame: 1.5 years after the randomization

  9. Miscarriage rate

    A clinically recognized pregnancy loss before 22 weeks of pregnancy. The denominator is the clinical pregnancy.

    Time frame: 22 weeks of pregnancy

  10. Birth weights of the newborns

    Birth weights of the newborns

    Time frame: 1 year after embryo transfer

07

Study locations

1 of 1 sites recruiting
  • ShangHai JIAI Genetics &I VF Institute
    Shanghai, China
    Recruiting
    • LI HE, MD · Contact+8613817223099
08

References and documents

Publications

  • Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992 Jul 4;340(8810):17-8. doi: 10.1016/0140-6736(92)92425-f. PubMed 1351601 ↗
  • Yeste M, Jones C, Amdani SN, Patel S, Coward K. Oocyte activation deficiency: a role for an oocyte contribution? Hum Reprod Update. 2016 Jan-Feb;22(1):23-47. doi: 10.1093/humupd/dmv040. Epub 2015 Sep 7. PubMed 26346057 ↗
  • Van Steirteghem AC, Nagy Z, Joris H, Liu J, Staessen C, Smitz J, Wisanto A, Devroey P. High fertilization and implantation rates after intracytoplasmic sperm injection. Hum Reprod. 1993 Jul;8(7):1061-6. doi: 10.1093/oxfordjournals.humrep.a138192. PubMed 8408487 ↗
  • De Vos A, Van De Velde H, Joris H, Verheyen G, Devroey P, Van Steirteghem A. Influence of individual sperm morphology on fertilization, embryo morphology, and pregnancy outcome of intracytoplasmic sperm injection. Fertil Steril. 2003 Jan;79(1):42-8. doi: 10.1016/s0015-0282(02)04571-5. PubMed 12524062 ↗
  • Lu YH, Gao HJ, Li BJ, Zheng YM, Ye YH, Qian YL, Xu CM, Huang HF, Jin F. Different sperm sources and parameters can influence intracytoplasmic sperm injection outcomes before embryo implantation. J Zhejiang Univ Sci B. 2012 Jan;13(1):1-10. doi: 10.1631/jzus.B1100216. PubMed 22205614 ↗
  • Greco E, Scarselli F, Fabozzi G, Colasante A, Zavaglia D, Alviggi E, Litwicka K, Varricchio MT, Minasi MG, Tesarik J. Sperm vacuoles negatively affect outcomes in intracytoplasmic morphologically selected sperm injection in terms of pregnancy, implantation, and live-birth rates. Fertil Steril. 2013 Aug;100(2):379-85. doi: 10.1016/j.fertnstert.2013.04.033. Epub 2013 May 23. PubMed 23706334 ↗
  • Vanden Meerschaut F, Nikiforaki D, Heindryckx B, De Sutter P. Assisted oocyte activation following ICSI fertilization failure. Reprod Biomed Online. 2014 May;28(5):560-71. doi: 10.1016/j.rbmo.2014.01.008. Epub 2014 Jan 31. PubMed 24656559 ↗
  • Vanden Meerschaut F, Nikiforaki D, De Gheselle S, Dullaerts V, Van den Abbeel E, Gerris J, Heindryckx B, De Sutter P. Assisted oocyte activation is not beneficial for all patients with a suspected oocyte-related activation deficiency. Hum Reprod. 2012 Jul;27(7):1977-84. doi: 10.1093/humrep/des097. Epub 2012 Apr 4. PubMed 22493027 ↗

Individual participant data

Plan to share: Yes — Data from the trial will be shared according to the International Committee of Medical Journal Editors guidelines. Individual participant data that underlie the results after deidentification (text, tables, figures and appendices) and the study protocol will be shared. On request, data can be shared with parties presenting relevant aims for the use of data. Data will be available from 3 months to 5 years following article publication.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available from 3 months to 5 years following article publication

Access criteria: On request, data can be shared with parties presenting relevant aims for the use of data. Please contact the researcher through email: lihe198900@163.com.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 78 non-industry interventional studies with no phase under Infertility, Male, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 28 months is close to that.

Counting every sponsor, half of 93 studies reached it within 34 months; a quarter within 17 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2024
First posted
Aug 20, 2024
StartActual
Aug 30, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2027
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06561451
Lead sponsor
ShangHai Ji Ai Genetics & IVF Institute
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Aug 30, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Feb 2, 2026

Study contacts

HE LI, MD
Contact
lihe198900@163.com
+8613817223099
Xiaoxi Sun, PhD
study director · Shanghai JiAi Genetics & IVF Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion